Human placenta/umbilical cord derivatives in regenerative medicine – Prospects and challenges

Abstract

The human placenta and umbilical cord, natural birth biowaste, are a housing unit for numerous bioactive macromolecules, growth factors, collagen and GAGs, with an array of high-quality stem cells. MSCs isolated from the human placenta and umbilical cord are utilized in both research and medical applications due to their sustainable sourcing, high viability, multipotent lineage and potency. They present an unprecedented opportunity in the tissue engineering, biomedical and biotechnology fields with minimal ethical constraints and nominal cost. Considering the world population and daily birth rates, with appropriate utilization and management, they could resolve the MSC shortage in the global stem cell therapy market and present biomedical waste disposal. A considerable number of clinical trials are presently underway where placenta-derived stem cells have been administered for different pathologies. Since the umbilical cord and placenta's primary function is to sustain the fetus until delivery, it has an ample supply of nutrients, proteins and essential factors necessary to assist cell viability and proliferation. Present research and medical applications include the fabrication of ECM-based nanofibers, disease models, micro-tissue, hybrid models and artificial implants. Future utilization of birthing biomedical waste in medical engineering and research will provide a rich and sustainable source of stem cells and extracellular matrix for enhanced biocompatibility and regeneration.